Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Selurampanel
BGG492 · 4 trials · 5 indications
Incidence of adrenal cortical adenomas as assessed by non-contrast MRI of the abdomen (CT or ultrasound of the abdomen was permitted if MRI was contraindication)
Incidence of uterine endometrial stromal sarcomas as assessed by sonogram/biopsy (females)
By measuring the number and percent of patients having any AE (advent event) by primary system organ class and/or preferred term. By laboratory, vital sign, and ECG data, summary statistics of values and change from baseline
| Arm | Type | Description |
|---|---|---|
| BGG492 | EXPERIMENTAL | This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day |
| Active | EXPERIMENTAL | - |
| Comparator | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Cohort 1 | EXPERIMENTAL | - |
| Cohort II | EXPERIMENTAL | - |
| Cohort III | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MRI, CT or ultrasound was permitted if MRI was contraindicated | PROCEDURE | MRI/CT/ultrasound of abdomen |
| Dexamethasone Supression Test | PROCEDURE | Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol |
| Sonogram | PROCEDURE | Sonogram of the uterus (females only) |
| Biopsy | PROCEDURE | Uterine endometrial biopsy (females only) |
| BGG492 | DRUG | No study-drug was administered in this study |
| Sumatriptan | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Written informed consent had to be obtained before any assessment was performed; 2. Patients had to be cooperative, willing to participate in the study assessments, and be able to report AEs (adverse events) themselves or have a caregiver who can record and report the events;...
BGG492 is an investigational small molecule being studied for several conditions, including photosensitive epilepsy, migraine, partial onset seizures, and adrenocortical adenoma. It is developed by Novartis AG and has been evaluated in Phase 2 clinical trials for these indications.
BGG492 is an investigational small molecule developed by Novartis AG. Its molecular target has not been disclosed in available clinical trial information. The drug has been studied in Phase 2 trials for conditions such as epilepsy and migraine.
BGG492 is developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker NVS. The drug is an investigational small molecule that has undergone Phase 2 clinical trials for several neurological and oncological conditions.
BGG492 is in Phase 2 clinical development. It has completed multiple Phase 2 trials, including studies in photosensitive epilepsy, migraine, and partial onset seizures. The drug is not approved and remains investigational.
BGG492 has been studied in several completed Phase 2 trials. These include NCT00784212 in photosensitive epilepsy, NCT00892203 in migraine, NCT01338805 in partial onset seizures, and NCT02150213, a safety follow-up study for patients with adrenocortical adenoma and other conditions.
BGG492 is an investigational small molecule developed by Novartis AG. No alternative names for BGG492 have been disclosed in clinical trial records. It is being studied for conditions such as epilepsy, migraine, and adrenocortical adenoma.